A1SN34 Stock Overview
A biopharmaceutical company, focuses on developing therapies for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Ascendis Pharma A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$48.42 |
52 Week High | US$52.90 |
52 Week Low | US$27.62 |
Beta | 0.59 |
1 Month Change | 0% |
3 Month Change | 0.88% |
1 Year Change | 60.44% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 36.97% |
Recent News & Updates
Recent updates
Shareholder Returns
A1SN34 | BR Biotechs | BR Market | |
---|---|---|---|
7D | 0% | 2.5% | -1.0% |
1Y | 60.4% | 1.8% | -2.4% |
Return vs Industry: A1SN34 exceeded the BR Biotechs industry which returned 1.8% over the past year.
Return vs Market: A1SN34 exceeded the BR Market which returned -2.4% over the past year.
Price Volatility
A1SN34 volatility | |
---|---|
A1SN34 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 4.6% |
10% most volatile stocks in BR Market | 9.2% |
10% least volatile stocks in BR Market | 2.1% |
Stable Share Price: A1SN34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A1SN34's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 879 | Jan Mikkelsen | ascendispharma.com |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S Fundamentals Summary
A1SN34 fundamental statistics | |
---|---|
Market cap | R$41.89b |
Earnings (TTM) | -R$2.88b |
Revenue (TTM) | R$1.89b |
22.1x
P/S Ratio-14.5x
P/E RatioIs A1SN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A1SN34 income statement (TTM) | |
---|---|
Revenue | €329.02m |
Cost of Revenue | €47.34m |
Gross Profit | €281.68m |
Other Expenses | €783.25m |
Earnings | -€501.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -8.75 |
Gross Margin | 85.61% |
Net Profit Margin | -152.44% |
Debt/Equity Ratio | -239.8% |
How did A1SN34 perform over the long term?
See historical performance and comparison